Reduced mortality associated with the use of ACE inhibitors in patients with type 2 diabetes

Diabetes Care

Volumn 27, Issue 6, 2004, Pages 1330-1334

  Eurich, Dean T ^a,b   Majumdar, Sumit R ^a,b   Tsuyuki, Ross T ^a,b   Johnson, Jeffrey A ^a,b,c  

^a INSTITUTE OF HEALTH ECONOMICS   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIARRHYTHMIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLYCERYL TRINITRATE; INSULIN; LOOP DIURETIC AGENT; METFORMIN; ORAL ANTIDIABETIC AGENT; RAMIPRIL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFECT; DRUG USE; ENZYME INHIBITION; EVALUATION; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; PROSPECTIVE STUDY; RISK ASSESSMENT; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; DATABASES, FACTUAL; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 2542422283     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.27.6.1330     Document Type: Article

References (27)

1. Erkens JA, Herings RM, Stolk RP, Spoelstra JA, Grobbee DE, Leufkens HG: Cardiovascular risk factors and diseases precede oral hypoglycaemic therapy in patients with type 2 diabetes mellitus. J Clin Epidemiol 55:345-349, 2002
2. Huang ES, Meigs JB, Singer DE: The effect of interventions to prevent cardiovascular disease in patients with type 2 diabetes mellitus. Am J Med 111:633-642, 2001
3. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 23 (Suppl. 1):S4-S19, 2000
4. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, Yale JF, Zinman B, Lillie D: 1998 clinical practice guidelines for the management of diabetes in Canada: Canadian Diabetes Association. CMAJ 159 (Suppl.):S1-S29, 1998
5. Lonn EM, Yusuf S, Jha P, Montague TJ, Teo KK, Benedict CR, Pitt B: Emerging role of angiotensin-converting enzyme inhibitors in cardiac and vascular protection. Circulation 90:2056-2069, 1994
6. Sleight P: Angiotensin II and trials of cardiovascular outcomes. Am J Cardiol 89: 11A-16A, 2002
7. EUROPA Investigators: Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 362:782-788, 2003
8. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G: Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342:145-153, 2000
9. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators: Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy: Heart Outcomes Prevention Evaluation Study Investigators. Lancet 355:253-259, 2000
10. Downey W, Beck P, McNutt M, Stang M, Osei W, Nichol J: Health databases in Saskatchewan. In Pharmacoepidemiology. 3rd ed. Strom BL, Ed. Chichester, U.K., John Wiley and Sons, 2000, p. 325-345
11. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with metformin use compared to sulfonylurea monotherapy in type 2 diabetes mellitus. Diabetes Care 25:2244-2248, 2002
12. Tsuyuki RT, Olson KL, Teo KK: Nitroglycerin as an indicator for the presence of coronary heart disease. Can Pharm J 132: 32-36, 1999
13. Connolly P, Cupples ME, Cuene-Grandidier H, Johnston D, Passmore P: The importance of validating the diagnosis of coronary heart disease when measuring secondary prevention: a cross-sectional study in general practice. Pharmacoepidemiol Drug Saf 11:311-317, 2002
14. Turner CJ, Parfrey P, Ryan K, Miller R, Brown A: Community pharmacist outreach program directed at physicians treating congestive heart failure. Am J Health Syst Pharm 57:747-752, 2000
15. Udris EM, Au DH, McDonell MB, Chen L, Martin DC, Tierney WM, Fihn SD: Comparing methods to identify general internal medicine clinic patients with chronic heart failure. Am Heart J 142:1003-1009, 2001
16. Clark DO, Von Korff M, Saunders K, Baluch WM, Simon GE: A chronic disease score with empirically derived weights. Med Care 33:783-795, 1995
17. Johnson RE, Hornbrook MC, Nichols GA: Replicating the chronic disease score (CDS) from automated pharmacy data. J Clin Epidemiol 47:1191-1199, 1994
18. Von Korff M, Wagner EH, Saunders K: A chronic disease score from automated pharmacy data. J Clin Epidemiol 45:197-203, 1992
19. D'Agostino RB Jr: Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 17:2265-2281, 1998
20. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 70:41-55, 1983
21. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 127:757-763, 1997
22. Gustafsson I, Torp-Pedersen C, Kober L, Gustafsson F, Hildebrandt P: Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction: Trace Study Group. J Am Coll Cardiol 34:83-89, 1999
23. Vijan S, Hayward RA: Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138:593-602, 2003
24. Zuanetti G, Latini R, Maggioni AP, Franzosi M, Santoro L, Tognoni G: Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 96:4239-4245, 1997
25. Ray WA, Griffin MR, Downey W: Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA 262:3303-3307, 1989
26. Spitzer WO, Suissa S, Ernst P, Horwitz RI, Habbick B, Cockcroft D, Boivin JF, McNutt M, Buist AS, Rebuck AS: The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506, 1992
27. Suissa S, Ernst P, Benayoun S, Baltzan M, Cai B: Low-dose inhaled corticosteroids and the prevention of death from asthma. N Engl J Med 343:332-336, 2000